• Publications
  • Influence
Decitabine improves patient outcomes in myelodysplastic syndromes
Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectlyExpand
  • 1,261
  • 71
  • PDF
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluatingExpand
  • 1,116
  • 61
  • PDF
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Recurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite theExpand
  • 425
  • 31
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies. Although there are extensive genetic dataExpand
  • 891
  • 28
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group ofExpand
  • 673
  • 25
  • PDF
p53 regulates hematopoietic stem cell quiescence.
The importance of the p53 protein in the cellular response to DNA damage is well known, but its function during steady-state hematopoiesis has not been established. We have defined a critical role ofExpand
  • 464
  • 25
L3MBTL1, a Histone-Methylation-Dependent Chromatin Lock
Distinct histone lysine methylation marks are involved in transcriptional repression linked to the formation and maintenance of facultative heterochromatin, although the underlying mechanisms remainExpand
  • 313
  • 20
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis
Transcription factors are frequently altered in leukaemia through chromosomal translocation, mutation or aberrant expression. AML1–ETO, a fusion protein generated by the t(8;21) translocation inExpand
  • 114
  • 19
  • PDF
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) who achieve complete response (CR) before autologous stem cell transplantation (ASCT) generally have better outcomesExpand
  • 344
  • 17
Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.
Transforming growth factor beta (TGFbeta) is one of few known negative regulators of hematopoiesis, yet the mechanisms by which it affects cell cycle arrest and stem cell quiescence are poorlyExpand
  • 204
  • 17